Major autohemotherapy (MAH) is a clinic procedure that withdraws a limited volume of blood into a sterile, anticoagulated container. A clinician introduces a measured oxygen–ozone mixture outside the body, mixes it with the blood, and returns the blood through the IV line. It must not involve direct injection of ozone gas into a vein.
MAH versus EBOO
MAH is a batch process, usually treating roughly 100–250 mL in one container. EBOO continuously circulates and processes a larger blood volume through an extracorporeal circuit, often with filtration. EBOO therefore has different access, anticoagulation, equipment, and monitoring risks.
Evidence and regulation
MAH is not FDA-approved to prevent or treat disease in the United States. Studies use heterogeneous ozone concentrations, doses, schedules, comparators, and outcomes. Broad claims for chronic infection, autoimmune disease, cancer, detoxification, cardiovascular disease, or anti-aging are not established. Do not replace proven treatment with MAH.
Clinic quality
A clinic should name the gas concentration and volume, blood volume, anticoagulant, container and tubing, single-use supplies, emergency plan, and clinician responsible. “Passes” or total ozone dose should be explained in measurable units rather than marketing language.